TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00846573
Drug: Hyperpolarized Helium-3
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
Study: NCT02962440
Drug: somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
Study: NCT00976404
Drug: ART intensification (raltegravir)
Normalized name: ethanol
DrugBank: Fica (DB03384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raltegravir 400 mg PO BID for 56 weeks
Study: NCT00976404
Drug: ART intensification (maraviroc)
Normalized name: ethanol
DrugBank: Fica (DB03384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Study: NCT00240396
Drug: Narcotics and NSAIDS
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00970996
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
Study: NCT00970996
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
Study: NCT00970996
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
Study: NCT02077868
Drug: MGN1703 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MGN1703 will be used as single agent maintenance treatment
Study: NCT03108469
Drug: IONIS-PKKRx (ISIS 546254)
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
Study: NCT04646044
Drug: Bempegaldesleukin
Normalized name: Bempegaldesleukin
DrugBank: Bempegaldesleukin (DB15140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT00882804
Drug: Hemin infusion
DrugBank: Hemin (DB03404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
Study: NCT01001195
Drug: bimatoprost ophthalmic solution 0.03%
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study: NCT03163303
Drug: nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day supply of nicotine patch
Study: NCT01915589
Drug: Refametinib (BAY86-9766)
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
Study: NCT01084824
Drug: Liquid nitrogen and cantharidin
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
Study: NCT01084824
Drug: Liquid nitrogen and topical placebo
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
Study: NCT04182828
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: both the drugs will be prepared in same volume, color, consistency and appearance
Study: NCT03527732
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy of albendazole (400 mg)
Study: NCT03527732
Drug: Albendazole and Ivermectin
Normalized name: Albendazole and ivermectin only product
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
Study: NCT02052388
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT02052388
Drug: Brilacidin
Normalized name: Brilacidin
DrugBank: Brilacidin (DB12997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Drug
Study: NCT00287378
Drug: omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: omalizumab as per weight and IgE
Study: NCT02207088
Drug: ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet
Study: NCT02207088
Drug: dasabuvir
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet
Study: NCT02207088
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet
Study: NCT01598506
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Study: NCT02367833
Drug: Combined Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
Study: NCT02367833
Drug: Transdermal Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
Study: NCT00623142
Drug: Hyperbaric Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Study: NCT01469377
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine was supplied in capsules.
Study: NCT03393988
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
Study: NCT02321176
Drug: trans-resveratrol
Normalized name: trans-resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient
Study: NCT03715348
Drug: Prothrombin Complex Concentrate (PCC)
Normalized name: human prothrombin complex concentrate (PCC)-lans 500 unit INTRAVEN VIAL (EA)
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
Study: NCT00722072
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
Study: NCT00722072
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
Study: NCT02203968
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Study: NCT00478023
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg IR; 4 - 6 hourly; Total 72 hours
Study: NCT02143388
Drug: IMRT combine with cisplatin concurrent chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
Study: NCT02753504
Drug: CKD-519
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03239106
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg BID daily
Study: NCT00369265
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30mg twice daily
Study: NCT04691076
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is administered by target-controlled infusion
Study: NCT04691076
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine is intravenously administrated
Study: NCT02699749
Drug: TAK-931
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 oral capsules.
Study: NCT02357368
Drug: Depot medroxyprogesterone acetate (DMPA)
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
Study: NCT00611026
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
Study: NCT00611026
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
Study: NCT02873377
Drug: Nicorette Gum
Normalized name: nicotine Chewing Gum [Nicorette]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Study: NCT02873377
Drug: Nicoderm CQ
Normalized name: Nicoderm CQ 21mg/24hr Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Study: NCT04573582
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg enasidenib (CC-90007)
Study: NCT01129596
Drug: donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
Study: NCT00251732
Drug: Standard dose (once daily) PPI plus low-dose antidepressant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
Study: NCT00251732
Drug: Rabeprazole , placebo, placebo
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
Study: NCT00343096
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses 0.1mg/kg once, repeat after 10 minutes x1
Study: NCT02964091
Drug: sofosbuvir/ledipasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03810105
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg twice daily (600mg total daily dose)
Study: NCT03810105
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg IV monthly
Study: NCT03725891
Drug: Aspirin 162 mg
Normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT03725891
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT04628325
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
Study: NCT00992797
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.
Study: NCT02872584
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
Study: NCT00973232
Drug: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
Study: NCT00973232
Drug: DDS-06C (650 mg acetaminophen and 75 mg tramadol)
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
Study: NCT00656669
Drug: sunitinib alone
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
Study: NCT00656669
Drug: sunitinib plus paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
Study: NCT01523041
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administrated subcutaneously (s.c., under the skin)
Study: NCT01523041
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administrated subcutaneously (s.c., under the skin)
Study: NCT00994123
Drug: MM-121
Normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-121 (SAR256212) = intravenous solution
Study: NCT00994123
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erlotinib = daily oral tablet
Study: NCT01553708
Drug: Epidermal growth factor with silver sulfadiazine cream
Normalized name: epidermal growth factor
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Study: NCT00396253
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
Study: NCT01093235
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01093235
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00219349
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg per day for 12 weeks
Study: NCT02149901
Drug: Pseudoephedrine + 480 ml water
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
Study: NCT02149901
Drug: Pseudoephedrine + 50 ml water
Normalized name: witch hazel
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
Study: NCT00000596
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000596
Drug: dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618228
Drug: Balsalazide
Normalized name: Balsalazide
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01737203
Drug: Viagra
Normalized name: Viagra
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet on Day 1 of each period
Study: NCT01737203
Drug: sildenafil ODT
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet on Day 1 of each period
Study: NCT02772159
Drug: TD-4208
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
Study: NCT02694289
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment/continuation of metformin therapy during admission
Study: NCT02694289
Drug: Subcutaneous (sliding scale) Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
Study: NCT00776074
Drug: Leuprorelin (GF)
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT00776074
Drug: Leuprorelin (GC)
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT04078425
Drug: Aldosterone Antagonists
Normalized name: Aldosterone antagonists
DrugBank: Aldosterone (DB04630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
Study: NCT02820493
Drug: vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01003769
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04045028
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
Study: NCT04045028
Drug: Daratumumab/rHuPH20
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
Study: NCT04045028
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
Study: NCT04045028
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion at a fixed dose of 1200 mg Q3W